Ameriprise Financial Inc. Decreases Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Ameriprise Financial Inc. lowered its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 20.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 97,885 shares of the company's stock after selling 24,717 shares during the period. Ameriprise Financial Inc. owned about 0.29% of TransMedics Group worth $6,103,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Freestone Grove Partners LP bought a new position in TransMedics Group during the 4th quarter worth $241,000. Emerald Mutual Fund Advisers Trust increased its stake in shares of TransMedics Group by 75.1% in the fourth quarter. Emerald Mutual Fund Advisers Trust now owns 219,275 shares of the company's stock valued at $13,672,000 after buying an additional 94,034 shares during the period. Northern Trust Corp increased its stake in shares of TransMedics Group by 12.7% in the fourth quarter. Northern Trust Corp now owns 354,622 shares of the company's stock valued at $22,111,000 after buying an additional 40,093 shares during the period. Aquatic Capital Management LLC raised its position in shares of TransMedics Group by 5.2% during the fourth quarter. Aquatic Capital Management LLC now owns 43,149 shares of the company's stock worth $2,690,000 after acquiring an additional 2,149 shares during the last quarter. Finally, Bullseye Asset Management LLC lifted its stake in shares of TransMedics Group by 31.9% in the fourth quarter. Bullseye Asset Management LLC now owns 47,754 shares of the company's stock worth $2,977,000 after acquiring an additional 11,553 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.

TransMedics Group Stock Down 0.7%

TransMedics Group stock traded down $0.93 during mid-day trading on Thursday, reaching $127.69. The stock had a trading volume of 546,564 shares, compared to its average volume of 1,357,560. The firm has a market capitalization of $4.32 billion, a PE ratio of 135.84 and a beta of 1.91. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The stock's 50-day simple moving average is $94.15 and its 200-day simple moving average is $78.41. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.29 by $0.41. The company had revenue of $143.54 million for the quarter, compared to analysts' expectations of $123.39 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. TransMedics Group's quarterly revenue was up 48.2% compared to the same quarter last year. During the same period last year, the business earned $0.35 EPS. On average, sell-side analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Activity

In other news, Director Edward M. Basile sold 5,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total value of $632,250.00. Following the transaction, the director now owns 2,866 shares in the company, valued at $362,405.70. This trade represents a 63.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David Weill sold 732 shares of TransMedics Group stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total value of $90,680.16. Following the transaction, the director now directly owns 12,134 shares in the company, valued at approximately $1,503,159.92. The trade was a 5.69% decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,732 shares of company stock worth $1,416,710 over the last three months. 7.00% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Canaccord Genuity Group restated a "buy" rating and set a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research note on Wednesday, April 23rd. Oppenheimer boosted their target price on shares of TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Finally, Piper Sandler reiterated an "overweight" rating and set a $125.00 price target (up from $105.00) on shares of TransMedics Group in a report on Friday, May 9th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $126.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.